Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial
Evaluate the effectiveness of a new ovarian stimulation (OS) protocol before IVF. Prospective clinical randomized trial. Private centers. Three hundred and twenty-three intended-to-treat women candidates for IVF. Patients were divided into three groups and administered the following treatments: grou...
Gespeichert in:
| Veröffentlicht in: | Fertility and sterility 2006-10, Vol.86 (4), p.830-838 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 838 |
|---|---|
| container_issue | 4 |
| container_start_page | 830 |
| container_title | Fertility and sterility |
| container_volume | 86 |
| creator | Serafini, Paulo Yadid, Isaac Motta, Eduardo L.A. Alegretti, Jose R. Fioravanti, Joyce Coslovsky, Marcio |
| description | Evaluate the effectiveness of a new ovarian stimulation (OS) protocol before IVF.
Prospective clinical randomized trial.
Private centers.
Three hundred and twenty-three intended-to-treat women candidates for IVF.
Patients were divided into three groups and administered the following treatments: group A, recombinant hFSH from day 3 until follicles reached 13–14mm, when recombinant hFSH was lowered to 75 IU daily and daily injections of 200 IU of hCG and a GnRH antagonist were administered until final maturation; group B, recombinant hFSH and a GnRH antagonist; group C, recombinant hFSH and a GnRH agonist.
Primary outcome was the number of mature oocytes. Secondary outcomes included average initial and total recombinant hFSH dosage, serum E
2 level on day of ovulation, number of oocytes retrieved, fertilization, number of top-quality embryos, endometrial thickness, implantation rate, pregnancy rate (PR), and incidence of ovarian hyperstimulation syndrome (OHSS).
The numbers of oocytes retrieved, mature oocytes, fertilization, top-quality embryos, and embryos transferred were comparable in all groups. Implantation rate, PR, and incidence of OHSS were also comparable. The total dose of recombinant hFSH was significantly lower in group A (1,674.7 ± 59.4 IU, vs. 2,197.9 ± 77.8 IU in group B and 2,156.7 ± 80.9 IU in group C).
This new OS protocol permits follicles and oocytes to fully develop, helps generate top-quality embryos, avoids premature ovulation, establishes clinical pregnancies, reduces administration of recombinant hFSH, minimizes costs, and does not increase the chances of OHSS. |
| doi_str_mv | 10.1016/j.fertnstert.2006.02.110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68938595</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0015028206011605</els_id><sourcerecordid>68938595</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-dd990c746965878d9331f313b66c5b6407a5b7508010cd6374de2d935e22063f3</originalsourceid><addsrcrecordid>eNqFkc-OEzEMxkcIxJaFV0C5wIkpTtJkZrjBin_SSnuBc5QmGeoqMylJ2tXuE_GYuLRSj1xiJf75i-2vaRiHJQeu32-XY8h1LpXOpQDQSxBLzuFJs-BK6VZpJZ82CwCuWhC9uGpelLIFAnknnjdXXA9awgoWzZ-7g81oZ1YqTvtoK6aZ3WPdMG8xPjB6CWxMMaKjbGa7jS2BWT_hjKXmE59GFtN96xOlNvuJ1NwmZcqgY7_SbH2qOe1wJqHMKByQ7uw4AkZ8_KfxgVm2y6nsgqt4CO9YtrNPEz4Gzyo1GF82z0YbS3h1jtfNzy-ff9x8a2_vvn6_-XjbupUStfV-GMB1KxpQ9V3vByn5KLlca-3UWq-gs2rdKeiBg_NadisfBFEqCAFajvK6eXvSpW5-70OpZsLiQox2DmlfjO4H2atBEdifQEdtlxxGs8s42fxgOJijS2ZrLi6Zo0sGhCGXqPT1-Y_9egr-Uni2hYA3Z8AWZ-NIy3BYLlwvgOaTxH06cYE2csCQTXEYZhc8Zlqk8Qn_381fwjq6Kg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68938595</pqid></control><display><type>article</type><title>Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Serafini, Paulo ; Yadid, Isaac ; Motta, Eduardo L.A. ; Alegretti, Jose R. ; Fioravanti, Joyce ; Coslovsky, Marcio</creator><creatorcontrib>Serafini, Paulo ; Yadid, Isaac ; Motta, Eduardo L.A. ; Alegretti, Jose R. ; Fioravanti, Joyce ; Coslovsky, Marcio</creatorcontrib><description>Evaluate the effectiveness of a new ovarian stimulation (OS) protocol before IVF.
Prospective clinical randomized trial.
Private centers.
Three hundred and twenty-three intended-to-treat women candidates for IVF.
Patients were divided into three groups and administered the following treatments: group A, recombinant hFSH from day 3 until follicles reached 13–14mm, when recombinant hFSH was lowered to 75 IU daily and daily injections of 200 IU of hCG and a GnRH antagonist were administered until final maturation; group B, recombinant hFSH and a GnRH antagonist; group C, recombinant hFSH and a GnRH agonist.
Primary outcome was the number of mature oocytes. Secondary outcomes included average initial and total recombinant hFSH dosage, serum E
2 level on day of ovulation, number of oocytes retrieved, fertilization, number of top-quality embryos, endometrial thickness, implantation rate, pregnancy rate (PR), and incidence of ovarian hyperstimulation syndrome (OHSS).
The numbers of oocytes retrieved, mature oocytes, fertilization, top-quality embryos, and embryos transferred were comparable in all groups. Implantation rate, PR, and incidence of OHSS were also comparable. The total dose of recombinant hFSH was significantly lower in group A (1,674.7 ± 59.4 IU, vs. 2,197.9 ± 77.8 IU in group B and 2,156.7 ± 80.9 IU in group C).
This new OS protocol permits follicles and oocytes to fully develop, helps generate top-quality embryos, avoids premature ovulation, establishes clinical pregnancies, reduces administration of recombinant hFSH, minimizes costs, and does not increase the chances of OHSS.</description><identifier>ISSN: 0015-0282</identifier><identifier>EISSN: 1556-5653</identifier><identifier>DOI: 10.1016/j.fertnstert.2006.02.110</identifier><identifier>PMID: 16963040</identifier><identifier>CODEN: FESTAS</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adult ; Biological and medical sciences ; Chorionic Gonadotropin - administration & dosage ; Combined Modality Therapy ; Drug Administration Schedule ; Female ; Fertilization in Vitro - methods ; Follicular Phase - drug effects ; Gynecology. Andrology. Obstetrics ; Humans ; in vitro fertilization ; low-dose hCG ; Medical sciences ; Ovarian Follicle - drug effects ; Ovarian stimulation ; Ovulation - drug effects ; Ovulation Induction - methods ; Pregnancy ; Pregnancy Rate ; Treatment Outcome</subject><ispartof>Fertility and sterility, 2006-10, Vol.86 (4), p.830-838</ispartof><rights>2006 American Society for Reproductive Medicine</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-dd990c746965878d9331f313b66c5b6407a5b7508010cd6374de2d935e22063f3</citedby><cites>FETCH-LOGICAL-c452t-dd990c746965878d9331f313b66c5b6407a5b7508010cd6374de2d935e22063f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0015028206011605$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18209653$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16963040$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serafini, Paulo</creatorcontrib><creatorcontrib>Yadid, Isaac</creatorcontrib><creatorcontrib>Motta, Eduardo L.A.</creatorcontrib><creatorcontrib>Alegretti, Jose R.</creatorcontrib><creatorcontrib>Fioravanti, Joyce</creatorcontrib><creatorcontrib>Coslovsky, Marcio</creatorcontrib><title>Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial</title><title>Fertility and sterility</title><addtitle>Fertil Steril</addtitle><description>Evaluate the effectiveness of a new ovarian stimulation (OS) protocol before IVF.
Prospective clinical randomized trial.
Private centers.
Three hundred and twenty-three intended-to-treat women candidates for IVF.
Patients were divided into three groups and administered the following treatments: group A, recombinant hFSH from day 3 until follicles reached 13–14mm, when recombinant hFSH was lowered to 75 IU daily and daily injections of 200 IU of hCG and a GnRH antagonist were administered until final maturation; group B, recombinant hFSH and a GnRH antagonist; group C, recombinant hFSH and a GnRH agonist.
Primary outcome was the number of mature oocytes. Secondary outcomes included average initial and total recombinant hFSH dosage, serum E
2 level on day of ovulation, number of oocytes retrieved, fertilization, number of top-quality embryos, endometrial thickness, implantation rate, pregnancy rate (PR), and incidence of ovarian hyperstimulation syndrome (OHSS).
The numbers of oocytes retrieved, mature oocytes, fertilization, top-quality embryos, and embryos transferred were comparable in all groups. Implantation rate, PR, and incidence of OHSS were also comparable. The total dose of recombinant hFSH was significantly lower in group A (1,674.7 ± 59.4 IU, vs. 2,197.9 ± 77.8 IU in group B and 2,156.7 ± 80.9 IU in group C).
This new OS protocol permits follicles and oocytes to fully develop, helps generate top-quality embryos, avoids premature ovulation, establishes clinical pregnancies, reduces administration of recombinant hFSH, minimizes costs, and does not increase the chances of OHSS.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Chorionic Gonadotropin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fertilization in Vitro - methods</subject><subject>Follicular Phase - drug effects</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>in vitro fertilization</subject><subject>low-dose hCG</subject><subject>Medical sciences</subject><subject>Ovarian Follicle - drug effects</subject><subject>Ovarian stimulation</subject><subject>Ovulation - drug effects</subject><subject>Ovulation Induction - methods</subject><subject>Pregnancy</subject><subject>Pregnancy Rate</subject><subject>Treatment Outcome</subject><issn>0015-0282</issn><issn>1556-5653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-OEzEMxkcIxJaFV0C5wIkpTtJkZrjBin_SSnuBc5QmGeoqMylJ2tXuE_GYuLRSj1xiJf75i-2vaRiHJQeu32-XY8h1LpXOpQDQSxBLzuFJs-BK6VZpJZ82CwCuWhC9uGpelLIFAnknnjdXXA9awgoWzZ-7g81oZ1YqTvtoK6aZ3WPdMG8xPjB6CWxMMaKjbGa7jS2BWT_hjKXmE59GFtN96xOlNvuJ1NwmZcqgY7_SbH2qOe1wJqHMKByQ7uw4AkZ8_KfxgVm2y6nsgqt4CO9YtrNPEz4Gzyo1GF82z0YbS3h1jtfNzy-ff9x8a2_vvn6_-XjbupUStfV-GMB1KxpQ9V3vByn5KLlca-3UWq-gs2rdKeiBg_NadisfBFEqCAFajvK6eXvSpW5-70OpZsLiQox2DmlfjO4H2atBEdifQEdtlxxGs8s42fxgOJijS2ZrLi6Zo0sGhCGXqPT1-Y_9egr-Uni2hYA3Z8AWZ-NIy3BYLlwvgOaTxH06cYE2csCQTXEYZhc8Zlqk8Qn_381fwjq6Kg</recordid><startdate>20061001</startdate><enddate>20061001</enddate><creator>Serafini, Paulo</creator><creator>Yadid, Isaac</creator><creator>Motta, Eduardo L.A.</creator><creator>Alegretti, Jose R.</creator><creator>Fioravanti, Joyce</creator><creator>Coslovsky, Marcio</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061001</creationdate><title>Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial</title><author>Serafini, Paulo ; Yadid, Isaac ; Motta, Eduardo L.A. ; Alegretti, Jose R. ; Fioravanti, Joyce ; Coslovsky, Marcio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-dd990c746965878d9331f313b66c5b6407a5b7508010cd6374de2d935e22063f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Chorionic Gonadotropin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fertilization in Vitro - methods</topic><topic>Follicular Phase - drug effects</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>in vitro fertilization</topic><topic>low-dose hCG</topic><topic>Medical sciences</topic><topic>Ovarian Follicle - drug effects</topic><topic>Ovarian stimulation</topic><topic>Ovulation - drug effects</topic><topic>Ovulation Induction - methods</topic><topic>Pregnancy</topic><topic>Pregnancy Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serafini, Paulo</creatorcontrib><creatorcontrib>Yadid, Isaac</creatorcontrib><creatorcontrib>Motta, Eduardo L.A.</creatorcontrib><creatorcontrib>Alegretti, Jose R.</creatorcontrib><creatorcontrib>Fioravanti, Joyce</creatorcontrib><creatorcontrib>Coslovsky, Marcio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fertility and sterility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serafini, Paulo</au><au>Yadid, Isaac</au><au>Motta, Eduardo L.A.</au><au>Alegretti, Jose R.</au><au>Fioravanti, Joyce</au><au>Coslovsky, Marcio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial</atitle><jtitle>Fertility and sterility</jtitle><addtitle>Fertil Steril</addtitle><date>2006-10-01</date><risdate>2006</risdate><volume>86</volume><issue>4</issue><spage>830</spage><epage>838</epage><pages>830-838</pages><issn>0015-0282</issn><eissn>1556-5653</eissn><coden>FESTAS</coden><abstract>Evaluate the effectiveness of a new ovarian stimulation (OS) protocol before IVF.
Prospective clinical randomized trial.
Private centers.
Three hundred and twenty-three intended-to-treat women candidates for IVF.
Patients were divided into three groups and administered the following treatments: group A, recombinant hFSH from day 3 until follicles reached 13–14mm, when recombinant hFSH was lowered to 75 IU daily and daily injections of 200 IU of hCG and a GnRH antagonist were administered until final maturation; group B, recombinant hFSH and a GnRH antagonist; group C, recombinant hFSH and a GnRH agonist.
Primary outcome was the number of mature oocytes. Secondary outcomes included average initial and total recombinant hFSH dosage, serum E
2 level on day of ovulation, number of oocytes retrieved, fertilization, number of top-quality embryos, endometrial thickness, implantation rate, pregnancy rate (PR), and incidence of ovarian hyperstimulation syndrome (OHSS).
The numbers of oocytes retrieved, mature oocytes, fertilization, top-quality embryos, and embryos transferred were comparable in all groups. Implantation rate, PR, and incidence of OHSS were also comparable. The total dose of recombinant hFSH was significantly lower in group A (1,674.7 ± 59.4 IU, vs. 2,197.9 ± 77.8 IU in group B and 2,156.7 ± 80.9 IU in group C).
This new OS protocol permits follicles and oocytes to fully develop, helps generate top-quality embryos, avoids premature ovulation, establishes clinical pregnancies, reduces administration of recombinant hFSH, minimizes costs, and does not increase the chances of OHSS.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>16963040</pmid><doi>10.1016/j.fertnstert.2006.02.110</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0015-0282 |
| ispartof | Fertility and sterility, 2006-10, Vol.86 (4), p.830-838 |
| issn | 0015-0282 1556-5653 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68938595 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Biological and medical sciences Chorionic Gonadotropin - administration & dosage Combined Modality Therapy Drug Administration Schedule Female Fertilization in Vitro - methods Follicular Phase - drug effects Gynecology. Andrology. Obstetrics Humans in vitro fertilization low-dose hCG Medical sciences Ovarian Follicle - drug effects Ovarian stimulation Ovulation - drug effects Ovulation Induction - methods Pregnancy Pregnancy Rate Treatment Outcome |
| title | Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T02%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ovarian%20stimulation%20with%20daily%20late%20follicular%20phase%20administration%20of%20low-dose%20human%20chorionic%20gonadotropin%20for%20in%20vitro%20fertilization:%20a%20prospective,%20randomized%20trial&rft.jtitle=Fertility%20and%20sterility&rft.au=Serafini,%20Paulo&rft.date=2006-10-01&rft.volume=86&rft.issue=4&rft.spage=830&rft.epage=838&rft.pages=830-838&rft.issn=0015-0282&rft.eissn=1556-5653&rft.coden=FESTAS&rft_id=info:doi/10.1016/j.fertnstert.2006.02.110&rft_dat=%3Cproquest_cross%3E68938595%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68938595&rft_id=info:pmid/16963040&rft_els_id=S0015028206011605&rfr_iscdi=true |